# US 2008/0287404 A1 · High Purity 17Alpha-Cyanomethyl-17Beta-Hydroxy-Estra-4,9-Diene-3- One and Process For the Syntheses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287404 A1
- Document ID: US20080287404A1
- Status: Published application
- Kind: A1
- Application number: 12/096,209
- Filed: 2006-10-11
- Published: 2008-11-20
- Earliest claimed: 2005-12-05
- Assignees: Richter Gedeon Vegyeszeti Gyar Rt.
- Inventors: Lajosne Dancsi; Sandor Maho; Antal Aranyi; Janos Horvath
- Web page: https://patentgrep.com/patent/US20080287404A1

## CPC

- C07J 41/0094: {containing nitrile radicals, including thiocyanide radicals}
- A61P 5/34: Gestagens
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/18: Feminine contraceptives
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a new process for the synthesis of high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I) from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V). The invention relates also to the high purity 17α-cyanomethyl-17β-hydroxy-estra-4,9-diene-3-one and pharmaceutical compositions containing that as active ingredient. The pharmaceutical compositions according to this invention contain high purity dienogest of formula (I) in which the total amount of impurities is less than 0.1%, while the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents. According to our invention the dienogest of formula (I) is synthesized the following way: i) 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V) is reacted with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating; ii) the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV) is reacted with cyanomethyl lithium at a temperature between 0 and −30° C.; iii) the obtained 3-methoxy-17α-cyanomethyl-17β-hydroxy-estra-2,5(10)-diene of formula (III) is reacted with a strong organic acid in tetrahydrofuran solution; iv) the obtained 17α-cyanomethyl-17β-hydroxy-estr-5(10)-ene-3-one of formula (II) is reacted with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60° C., then the obtained crude dienogest of formula (I) is purified by recrystallization and preparative HPLC.

## Claims

### Claim 1

A new process for the synthesis of high purity 17α-cyanomethyl-17β-cydroxy-estra-4,9-diene-3-one (further on dienogest) of formula (I)
from 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V), characterized by i) reacting the 3-methoxy-17-hydroxy-estra-2,5(10)-diene of formula (V)
with aluminum isopropylate in the presence of cyclohexanone in an inert organic solvent under heating ii) then reacting the so obtained 3-methoxy-estra-2,5(10)-diene-17-one of formula (IV)
with cyanomethyl lithium at a temperature between 0 and −30° C., iii) then reacting the obtained 3-methoxy-17α-cyanomethyl-17β-cydroxy-estra-2,5(10)-diene of formula (III)
with a strong organic acid in tetrahydrofuran solution, iv) reacting the obtained 17α-cyanomethyl-17β-cydroxy-estr-5(10)-ene-3-one of formula (II)
with 1-1.5 equivalent of pyridinium tribromide in pyridine solution at a temperature between 0 and 60° C., then purifying the obtained crude dienogest of formula (I) by recrystallization and preparative HPLC.

### Claim 2 (depends on 1)

The process according to claim 1 wherein the oxidation of step i) is carried out in toluene in the presence of 20-25 equivalent of cyclohexanone between 100 and 120° C.

### Claim 3 (depends on 1)

The process according to claim 1, further comprising the step of:
preparing the cyanomethyl lithium reagent of step ii) in situ from hexyllithium and acetonitrile.

### Claim 4 (depends on 1)

The process according to claim 1, further comprising the step of:
carrying out the cyanomethylation reaction of step ii) between 0 and −30° C.

### Claim 5 (depends on 1)

The process according to claim 1 wherein the cyanomethylation reaction of step ii) is carried out at between −10 and −20° C.

### Claim 6 (depends on 1)

The process according to claim 1 wherein 2 equivalent of cyanomethyl lithium reagent is used in step ii).

### Claim 7 (depends on 1)

The process according to the claim 1 wherein the acidic treatment of step iii) is carried out with a di- or tribasic organic acid in tetrahydrofuran.

### Claim 8 (depends on 1)

The process according to claim 1 wherein the acidic treatment of step iii) is carried out with 2 equivalent of oxalic acid dihydrate.

### Claim 9 (depends on 1)

The process according to claim 1, further comprising the step of:
reacting the compound of formula (II) with 1.05 equivalent of pyridinium tribromide in step iv).

### Claim 10 (depends on 1)

The process according to claim 1, further comprising the step of:
reacting the compound of formula (II) with pyridinium tribromide between 0 and 60° C. in step iv).

### Claim 11 (depends on 1)

The process according to claim 1, further comprising the step of:
reacting the compound of formula (II) with pyridinium tribromide between 25 and 50° C.

### Claim 12 (depends on 1)

The process according to claim 1, further comprising the step of:
purifying the dienogest of formula (I) by HPLC using silica gel as adsorbent.

### Claim 13 (depends on 1)

The process according to claim 1, further comprising the step of:
purifying the dienogest of formula (I) by HPLC using the following solvent mixtures as eluents: 70:30 dichloromethane/ethyl acetate or 80:20 dichioromethane/tert-butyl methyl ether or 90:10 dichloromethane/acetone.

### Claim 14 (depends on 1)

The process according to claim 1, further comprising the step of:
recrystallizing the dienogest of formula (I) obtained by preparative HPLC from ethyl acetate, acetone, tert-butyl methyl ether, diisopropyl ether, acetonitrile, methanol, ethanol or aqueous mixture of different ratio of these solvents.

### Claim 15

High-purity dienogest of formula (I) in which the total amount of impurities is less than 0.1% and the amount of 4-bromo-dienogest is under the detection limit (0.02%).

### Claim 16

Pharmaceutical compositions containing high-purity dienogest of formula (I) in which the total amount of impurities is less than 0.1% and the amount of 4-bromo-dienogest is under the detection limit (0.02%) as active ingredient or at least one of the active ingredients and auxiliary materials, which are commonly used in practice, such as carriers, excipients or diluents.
